Papers3196279

Substance use disorders and comorbid Axis I and II psychiatric disorders among young psychiatric patients: findings from a large electronic health records database

Journal of psychiatric research · 01-11-2011 · 3196279 on PMC →
Entities in this paper
Abnormal female sex hormone inpatient psychiatric treatment Cannabis use disorder Psychoactive substance use disorder Substance Use Disorder Leukocyte Nuclear Appendages, Hereditary Prevalence of Psychiatric treatment changed

Extracted findings (3)

Among youth psychiatric patients with a substance use disorder, children aged 2-12 years and females had significantly higher rates of comorbid anxiety disorder diagnoses than adolescents aged 13-17 y

Effect: decline; Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; females ages 13-17: 18.5% AD vs males 9.1%

Size: Ages 2-12: 36.5% AD prevalence vs 12.1% for ages 13-17; fema

Among youth psychiatric patients with a substance use disorder, younger age at first treatment (2-12 vs 13-17), female sex, and black race were each independently associated with substantially higher

Effect: decline; AOR 3.50 for ages 2-12 vs 13-17; AOR 2.48 for female vs male; AOR 3.26 for black vs white; CI: 95% CI 2.11-5.80 (ages 2-12); 95% CI 1.92-3.21

Size: AOR 3.50 for ages 2-12 vs 13-17; AOR 2.48 for female vs male CI: 95% CI 2.11-5.80 (ages 2-12); 95% CI 1.9

Cannabis diagnosis was the most prevalent substance use disorder across all age, sex, racial/ethnic, and treatment setting groups among youth psychiatric patients, accounting for more than 80% of all

Effect: decline; Cannabis SUD 10.4% of all patients; >80% of all SUD cases; 21.2% among ages 13-17

Size: Cannabis SUD 10.4% of all patients; >80% of all SUD cases; 2